An innovative medication developed in Australia, designed to alleviate the challenging symptoms of dementia, is currently under trial in multiple states across the country. Dementia often brings about significant behavioural and psychological changes that distress both patients and their families, with agitation and aggression being particularly difficult to manage. Associate Professor Michael Woodward, Director of the Austin Health Aged Care and Memory Clinic, emphasises that these shifts in behaviour can be more complex to handle than memory loss alone.
The trial involves a new drug, KNX100, which aims to serve as a safer alternative to traditional antipsychotics, typically used as a last resort due to their undesirable side effects. Principal Investigator Dr Peter de Wet stresses the necessity for targeted treatments that mitigate severe side effects, particularly drowsiness. There is a growing call for medications that not only address symptoms without heavy sedation but also improve the quality of life for those affected by dementia.
Recruitment is underway for 60 dementia patients living at home across Queensland, New South Wales, Victoria, and South Australia to participate in these trials. Preliminary studies suggest that KNX100 is both safe and well-tolerated by patients. The drug works by inhibiting an enzyme in the brain associated with the signalling pathway leading to agitation and aggression, symptoms that can severely impact a patient’s well-being.
This development is rooted in research conducted at the University of Sydney and is being further advanced by Kinoxis Therapeutics. CEO Hugh Alsop expresses optimism about addressing this significant unmet need in dementia care through dedicated investment and efforts towards obtaining regulatory approval for the drug.
Patients in Victoria, New South Wales, and South Australia interested in the study can find additional information on the trial’s official website.